Study summary
With first-line avelumab, about 4 in 10 people with spread Merkel cell cancer were alive at 4 years
38%alive at 4 years
What was tested
Avelumab, an immunotherapy, as the first treatment for metastatic Merkel cell carcinoma, followed for more than 4 years.
What they found
- 38% were alive at 4 years; median survival was 20.3 months.
- Survival compares well with older chemotherapy results.
What it means
Merkel cell carcinoma was once treated mainly with chemotherapy that rarely gave lasting control.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.